These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

723 related articles for article (PubMed ID: 29176657)

  • 21. Lipids: a personal view of the past decade.
    Katsiki N; Mikhailidis DP
    Hormones (Athens); 2018 Dec; 17(4):461-478. PubMed ID: 30229482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Personalized medicine in lipid-modifying therapy.
    Tomlinson B; Lin CH; Chan P; Lam CW
    Per Med; 2021 Mar; 18(2):185-203. PubMed ID: 33565320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of dyslipidemia in HIV.
    Sekhar RV
    Curr Atheroscler Rep; 2015 Apr; 17(4):493. PubMed ID: 25702057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of conventional lipid-lowering therapy on circulating levels of PCSK9: protocol for a systematic review and meta-analysis of randomised controlled trials.
    Luo J; Huang T; Xu R; Wang X; Yang Y; Li L; Zhang X; Zhang Y; Yang R; Wang J; Yang H; Ma Y; Yang B; Wang T; Jiao L
    BMJ Open; 2022 Sep; 12(9):e061884. PubMed ID: 36691198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

  • 26. Glycaemic Effects of Non-statin Lipid-Lowering Therapies.
    Collins PD; Sattar N
    Curr Cardiol Rep; 2016 Dec; 18(12):133. PubMed ID: 27864787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment approaches for diabetes and dyslipidemia.
    Wu M; Lyons TJ
    Horm Res Paediatr; 2011; 76 Suppl 1(Suppl 1):76-80. PubMed ID: 21778754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current status of lipid management in acute coronary syndrome.
    Fujisue K; Tsujita K
    J Cardiol; 2017 Aug; 70(2):101-106. PubMed ID: 28325524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipids and Cerebrovascular Disease: Research and Practice.
    Yaghi S; Elkind MS
    Stroke; 2015 Nov; 46(11):3322-8. PubMed ID: 26451029
    [No Abstract]   [Full Text] [Related]  

  • 31. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
    O'Keefe JH; DiNicolantonio JJ; Lavie CJ
    Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Clinical Guide to Combination Lipid-Lowering Therapy.
    Russell C; Sheth S; Jacoby D
    Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Multimodal therapy of dyslipidemia].
    Stahn A; Hanefeld M
    Clin Res Cardiol Suppl; 2011 May; 6():10-6. PubMed ID: 22528173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future.
    Hajhosseiny R; Sabir I; Khavandi K; Wierzbicki AS
    Clin Pharmacol Ther; 2014 Jul; 96(1):64-73. PubMed ID: 24699033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should hyperlipidemia in children with the nephrotic syndrome be treated?
    Querfeld U
    Pediatr Nephrol; 1999 Jan; 13(1):77-84. PubMed ID: 10100296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Currently available hypolipidaemic drugs and future therapeutic developments.
    Farmer JA; Gotto AM
    Baillieres Clin Endocrinol Metab; 1995 Oct; 9(4):825-47. PubMed ID: 8593127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An updated review of lipid-modifying therapy.
    Simons LA
    Med J Aust; 2019 Jul; 211(2):87-92. PubMed ID: 31006138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs.
    Toth PP
    Drugs; 2010 Jul; 70(11):1363-79. PubMed ID: 20614945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism of action of niacin.
    Kamanna VS; Kashyap ML
    Am J Cardiol; 2008 Apr; 101(8A):20B-26B. PubMed ID: 18375237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
    Streja E; Streja DA; Soohoo M; Kleine CE; Hsiung JT; Park C; Moradi H
    Semin Nephrol; 2018 Jul; 38(4):369-382. PubMed ID: 30082057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.